ADARB2 and glioma: Among them, IGF2BP3 (HR: 2.165, 95%CI: 1.547–3.030, p < 0.001), NSUN7 (HR: 2.611, 95%CI: 1.226–5.561, p = 0.013), EXO1 (HR: 3.624, 95%CI: 1.978–3.030, p < 0.001), FBXO17 (HR: 2.109, 95%CI: 1.161–3.831, p = 0.014), ANG (HR: 2.717, 95%CI: 1.454–5.078, p = 0.002) and ADARB2 (HR: 1.979, 95%CI: 1.308–2.992, p = 0.001) were negatively correlated with survival time for glioma patients.